RubrYc Therapeutics Announces Series A2 Preferred Equity Financing, Collaboration, and RTX-003 License with iBio, Inc.
RubrYc Therapeutics, Inc. ("RubrYc") and iBio, Inc. ("iBio", NYSEA: IBIO) announced today the closing of RubrYc's Series A2 Preferred Financing, and concomitant License and Collaboration Agreements directed towards the research.
August 26, 2021
by firstwordpharma
iBio Expands Immuno-Oncology Pipeline in AI Partnership with RubrYc Therapeutics
iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company" today announced that it has signed a definitive worldwide exclusive license agreement with RubrYc Therapeutics, Inc., ("RubrYc") for RTX-003, an immunotherapy candidate targeting regulatory T cells (Tregs).
August 26, 2021
by firstwordpharma
atbtherapeutics Enters Manufacturing Agreement with iBio CDMO
atbtherapeutics, a biopharmaceutical company building an oncology pipeline using its antibody–toxin-bioengineered “atbody,” has entered a long-term manufacturing agreement with iBio CDMO, a global leader in plant-based biologics manufacturing located ...
December 10, 2020
by contractpharma
iBio to Provide CDMO Services for ATB Therapeutics
iBio will produce ATB’s bioengineered antibody-toxin fusion proteins.
December 4, 2020
by contractpharma
iBio Enters into Agreement with Safi Biosolutions
iBio, a biotech innovator and biologics contract manufacturing organization (CMO), has entered into a Master Services Agreement (MSA) with Boston-based Safi Biosolutions to evaluate iBio’s FastPharming System for the expression of key proteins to be ...
October 10, 2020
by contractpharma
iBio Advances COVID-19 Vaccine Candidate
IBIO-201 induced the production of anti-spike neutralizing antibodies in tests.
September 14, 2020
by contractpharma
iBio Signs License Agreement with Planet Biotechnology for COVID-19 Therapeutic
iBio Inc., a biotechnology innovator and biologics contract manufacturing organization, has entered into an exclusive worldwide license agreement with Planet Biotechnology Inc. for the development of Planet’s COVID-19 therapeutic candidate, ACE2-Fc.
September 2, 2020
by contractpharma
iBio Receives IBM Clinical Development Solution
Designed to support clinical COVID-19 vaccine candidates.
July 2, 2020
by contractpharma
iBio Expands COVID-19 Vaccine Collaboration
Now includes the Infectious Disease Research Institute to help lead pre-clinical development and clinical trial oversight.
April 14, 2020
by contractpharma
iBio Developing Proprietary COVID-19 Vaccine Candidates
iBio, Inc., a biologics contract manufacturing organization (CMO) and biotechnology company, is progressing towards developing vaccine candidates for preventing infection ...
March 23, 2020
by contractpharma
iBio Announces Collaboration with EdgePoint AI for Next Gen Quality in Biologics Manufacturing
Using blockchain technology, TrustPoint Fabric enables automated data generation and capture to remain immutable and fully auditable.
December 24, 2019
by firstwordpharma
iBio, AzarGen Biotechnologies Expand Mfg. Pact
iBio, Inc. has entered into the initial Statement of Work (SOW1) under its Memorandum of Understanding (MOU) with AzarGen Biotechnologies.
September 20, 2019
by contractpharma